GT Biopharma Inc (NASDAQ:GTBP)’s traded shares stood at 0.13 million during the last session, with the company’s beta value hitting 1.37. At the close of trading, the stock’s price was $2.8, to imply a decrease of -9.72% or -$0.3 in intraday trading. The GTBP share’s 52-week high remains $4.10, putting it -46.43% down since that peak but still an impressive 38.57% since price per share fell to its 52-week low of $1.72. The company has a valuation of $8.80M, with an average of 96860.0 shares in intraday trading volume over the past 10 days and average of 60.43K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for GT Biopharma Inc (GTBP), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give GTBP a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
GT Biopharma Inc (NASDAQ:GTBP) trade information
After registering a -9.72% downside in the last session, GT Biopharma Inc (GTBP) has traded red over the past five days. The 5-day price performance for the stock is -26.45%, and -0.89% over 30 days. With these gigs, the year-to-date price performance is 5.08%. Short interest in GT Biopharma Inc (NASDAQ:GTBP) saw shorts transact 0.22 million shares and set a 2.21 days time to cover.
GT Biopharma Inc (GTBP) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 54.16% for the past 5-year period. While 2025 is set for a 71.90% return in earnings, projections for the next 5 years are at 50.14% annually.
GTBP Dividends
GT Biopharma Inc has its next earnings report out on 2025-May-15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
GT Biopharma Inc (NASDAQ:GTBP)’s Major holders
GT Biopharma Inc insiders hold 23.16% of total outstanding shares, with institutional holders owning 18.98% of the shares at 24.70% float percentage. In total, 18.98% institutions holds shares in the company, led by DEKABANK DEUTSCHE GIROZENTRALE. As of 2024-06-30, the company held over 0.98 million shares (or 57.1486% of shares), all amounting to roughly $37.83 million.
The next major institution holding the largest number of shares is BANK OF MONTREAL /CAN/ with 29872.0 shares, or about 1.7449% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $93201.0.
We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the GT Biopharma Inc (GTBP) shares. Going by data provided on Apr 30, 2025, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 12.81 shares. This is just over 0.41% of the total shares, with a market valuation of $35798.0. Data from the same date shows that the other fund manager holds a little less at 10.5, or 0.33% of the shares, all valued at about 29358.0.
